Neoadjuvant therapy is any cancer treatment given before the primary treatment, which is almost always surgery. The word itself comes from the Latin “neo” (new) and “adjuvant” (to help), and it typically means chemotherapy, immunotherapy, radiation, or some combination delivered in the weeks or months before a tumor is removed. The concept has been around since the 1980s, when oncologists first tried presurgical chemotherapy to shrink large breast tumors that couldn’t otherwise be operated on. Since then, neoadjuvant treatment has expanded into lung, rectal, bladder, esophageal, melanoma, and pediatric cancers, and the arrival of immunotherapy has accelerated that expansion dramatically.
Why Treat Before Surgery
The logic of neoadjuvant therapy rests on a few practical advantages that surgery alone can’t offer. First, shrinking a tumor before the operation can turn an impossible or disfiguring surgery into a feasible one. A breast tumor too large for a lumpectomy might shrink enough to allow breast-conserving surgery instead of mastectomy. A rectal tumor threatening the sphincter might shrink enough to preserve normal bowel function. In breast cancer specifically, neoadjuvant therapy was first introduced in the 1980s to downstage large, inoperable tumors and enable less extensive resections, and is now increasingly used even in patients with smaller tumors.1memo – Magazine of European Medical Oncology. Neoadjuvant therapy
Second, treating early gives systemic drugs access to the full, intact tumor and its blood supply, which may make the drugs more effective than they’d be against microscopic leftover cells after surgery. Third, the response to neoadjuvant therapy provides real-time information. If a tumor melts away, that’s strong evidence the drugs are working. If it barely changes, oncologists know they need to pivot. And in the era of immunotherapy, there’s a fourth rationale: the intact tumor acts as a reservoir of signals that can prime the immune system more effectively than a scar where the tumor used to be.
What Pathologic Complete Response Means
When surgeons remove tissue after neoadjuvant therapy, a pathologist examines it under the microscope to see how much cancer is left. If no viable tumor cells remain in either the primary site or the lymph nodes, that’s called a pathologic complete response, or pCR. It doesn’t just mean the drugs worked well in the short term. Across many cancers, achieving pCR is one of the strongest signals that a patient will survive long-term.
A large meta-analysis of over 23,000 breast cancer patients found that those who achieved pCR after neoadjuvant chemotherapy had dramatically better overall survival compared to those who didn’t, with roughly a 78% lower risk of death.2PubMed Central. Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis The pattern holds in lung cancer too. A meta-analysis of non-small cell lung cancer patients treated with neoadjuvant chemotherapy found that those achieving pCR had about half the risk of death compared to those without pCR, with five-year survival rates of roughly 63% versus 39%.3JTO Clinical and Research Reports. Association of Pathologic Complete Response and Long-Term Survival Outcomes Among Patients Treated With Neoadjuvant Chemotherapy or Chemoradiotherapy for NSCLC: A Meta-Analysis
Because pCR predicts long-term outcomes so reliably, regulators have started accepting it as a surrogate endpoint to speed up drug approvals. If a new drug pushes pCR rates significantly higher in a well-designed trial, the FDA may grant accelerated approval without waiting years for overall survival data to mature. This has been particularly influential in breast cancer, where pCR has become a key endpoint for evaluating escalated treatment strategies in aggressive subtypes like HER2-positive and triple-negative disease.4PubMed. Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer
How Response Is Measured Beyond pCR
Pathologic complete response is a binary measure: either the tumor is completely gone or it’s not. But oncologists increasingly recognize that the amount of residual disease matters on a spectrum. The residual cancer burden, or RCB, is a continuous score that captures how much cancer remains after treatment, factoring in the size of the residual tumor bed and how many lymph nodes are involved. In a pooled analysis of over 5,000 breast cancer patients, each unit increase in RCB score was associated with meaningfully worse long-term outcomes across every breast cancer subtype.5PubMed Central. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients Patients in the highest residual disease category had roughly twelve times the risk of recurrence compared to those with pCR.6Scientific Reports. Prognostic value of residual cancer burden after neoadjuvant chemotherapy in breast cancer: a comprehensive subtype-specific analysis
RCB has a practical consequence beyond prognosis. A patient who achieves pCR might be spared additional aggressive therapy after surgery, while a patient with substantial residual disease can be given additional drugs to reduce the risk of relapse. This kind of treatment personalization, adjusting what happens after surgery based on what the pathologist finds, is one of the central promises of the neoadjuvant approach.
Imaging tools also play a role before the tumor is even removed. PET scans and MRI are used during neoadjuvant treatment to track whether the tumor is responding. Research in breast cancer suggests that changes in PET metabolic activity and MRI perfusion during treatment can predict which patients will achieve a good pathologic response, with PET and MRI measurements providing complementary information.7PubMed Central. Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer And circulating tumor DNA, fragments of tumor genetic material shed into the bloodstream, is emerging as a promising blood-based marker. Rapid clearance of circulating tumor DNA during treatment is strongly linked to favorable outcomes, while persistent levels suggest a patient may not be responding.8PubMed Central. Circulating tumor DNA dynamics predict pathological response and guide therapy personalization in the neoadjuvant setting
The Immunotherapy Revolution in Lung Cancer
Nowhere has neoadjuvant therapy changed faster than in non-small cell lung cancer. For decades, chemotherapy before surgery offered a modest benefit at best. The addition of the immune checkpoint inhibitor nivolumab to standard chemotherapy in the CheckMate 816 trial changed the picture substantially. The combination pushed the pCR rate from about 2% with chemotherapy alone to 24%, and median event-free survival jumped from roughly 21 months to over 31 months.9PubMed Central. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer Those are not small incremental gains; they represent a fundamentally different level of tumor response.
Several other trials since then have confirmed the pattern, and neoadjuvant chemoimmunotherapy is now considered the global standard of care for patients with resectable stage IB through IIIA non-small cell lung cancer.10Journal for ImmunoTherapy of Cancer. Neoadjuvant chemoimmunotherapy in non-small cell lung cancer: evolving resectability criteria, biomarker-driven postoperative management, and emerging therapeutic strategies The success here has also started challenging what surgeons consider operable. Some tumors that would once have been labeled too advanced for surgery are now being reconsidered after impressive shrinkage with chemoimmunotherapy.
Neoadjuvant Immunotherapy in Melanoma
Melanoma is another cancer where neoadjuvant immunotherapy has shown striking results. The NADINA trial tested giving the combination of nivolumab and ipilimumab before surgery in patients with resectable stage III melanoma, compared to the standard approach of surgery first followed by adjuvant nivolumab. The neoadjuvant group had an estimated twelve-month event-free survival of about 84%, compared to roughly 57% in the adjuvant group. The risk of disease progression, recurrence, or death was reduced by about two-thirds with the neoadjuvant approach.11PubMed. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma Earlier phase 1 and 2 studies had already shown high pathologic response rates with this combination, building the evidence that treating before surgery produces a stronger immune response against the tumor.12Nature Medicine. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
There’s an immunological rationale for why the neoadjuvant setting may be particularly powerful for checkpoint blockade. When the intact tumor is still present, the immune system has a broader set of antigens to recognize and respond to. Removing the tumor first and then starting immunotherapy means the immune system has less to work with. This biological logic applies broadly, not just to melanoma, and helps explain the wave of neoadjuvant immunotherapy trials across cancer types.13Science. Neoadjuvant checkpoint blockade for cancer immunotherapy
Rectal Cancer and the Possibility of Skipping Surgery
In locally advanced rectal cancer, neoadjuvant therapy has evolved from a simple course of radiation with chemotherapy into what’s called total neoadjuvant therapy, or TNT, which moves all the chemotherapy to before surgery as well. The payoff is substantial. A meta-analysis found that TNT roughly doubled the pCR rate compared to the older approach, with about 30% of patients achieving a complete pathologic response versus about 15%.14JAMA Network Open. Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-analysis A network meta-analysis comparing different TNT sequences found that several combinations of radiation and chemotherapy outperformed the traditional approach for achieving pCR, though certain sequences showed trade-offs with locoregional recurrence rates.15JAMA Network Open. Treatment of Locally Advanced Rectal Cancer in the Era of Total Neoadjuvant Therapy: A Systematic Review and Network Meta-Analysis
The most exciting development in rectal cancer is what happens when the tumor disappears entirely. If imaging and examination after TNT show no detectable cancer, some patients can enter a “watch and wait” program, skipping major surgery altogether. Rectal surgery often means a permanent or temporary ostomy bag, and the functional consequences for bowel, bladder, and sexual function can be severe. Avoiding that operation while still being cured is enormously appealing. In one prospective series of TNT-treated patients, about a third achieved a clinical complete response and entered watch-and-wait; only 6% of those developed tumor regrowth.16PubMed Central. Organ Preservation in Patients with Rectal Cancer Treated with Total Neoadjuvant Therapy This approach is still considered selective and requires close monitoring, but it represents one of the most tangible quality-of-life benefits of aggressive neoadjuvant therapy.17PubMed Central. Watch and Wait Approach for Rectal Cancer
Quality-of-life research on patients who entered watch-and-wait programs versus those who had surgery shows some intriguing patterns. Patients who avoided surgery tended to see gradual improvements in role functioning and reductions in anxiety over time, while those who had local excision saw quick improvements in emotional distress but also experienced increased bowel dysfunction and, in men, reduced sexual function.18PubMed Central. Quality of life and functional outcomes after rectal sparing approaches following neoadjuvant therapy for rectal cancer: a prospective cohort multicentre study Chronic treatment-related side effects from the neoadjuvant therapy itself, along with the duration of the treatment course, were significant factors affecting quality of life regardless of whether surgery was avoided.19PubMed Central. Quality of life following total neoadjuvant therapy for rectal cancer
Bladder, Esophageal, and Pancreatic Cancers
Neoadjuvant therapy isn’t equally mature across all cancer types. In muscle-invasive bladder cancer, cisplatin-based chemotherapy before surgery has been standard for years, though the absolute survival benefit is modest: about a 5% improvement in five-year survival and a roughly 14% relative reduction in the risk of death. In one landmark trial, median overall survival was 77 months with neoadjuvant chemotherapy versus 46 months with surgery alone, and pCR rates with the standard regimen ran around 33%.20PubMed Central. Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest Developments A significant challenge here is that many bladder cancer patients are older and have kidney function too impaired to tolerate cisplatin-based chemotherapy. Immunotherapy combinations are being tested to fill that gap.
Esophageal cancer has been a battleground between two neoadjuvant strategies. One approach uses chemoradiation before surgery; the other uses chemotherapy both before and after surgery, a “perioperative” approach. The large ESOPEC trial compared perioperative chemotherapy against neoadjuvant chemoradiation in esophageal adenocarcinoma and found that the chemotherapy-based approach yielded a median overall survival of 66 months versus 37 months, with five-year survival rates of about 51% versus 39%.21OncLive. Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer That result has shifted practice in many centers, though debate continues about whether the findings apply equally to squamous cell carcinoma of the esophagus.
In pancreatic cancer, the story is more tentative. A meta-analysis of randomized trials comparing neoadjuvant therapy to upfront surgery for resectable pancreatic cancer found a trend toward fewer major postoperative complications with the neoadjuvant approach, but the results didn’t reach statistical significance, and there was considerable variation between studies.22PubMed Central. Comparison of efficacy and safety between neoadjuvant therapy and surgical treatment for resectable pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials Pancreatic cancer is one area where enthusiasm for neoadjuvant treatment runs ahead of the evidence, partly because the surgery itself is so demanding and recurrence rates are so high that any strategy offering better patient selection feels worth pursuing.
Risks and Limitations
Neoadjuvant therapy is not risk-free, and the most straightforward concern is that the tumor grows while you’re treating it. In a large breast cancer series of nearly 2,000 patients receiving neoadjuvant chemotherapy, about 3% had disease progression during treatment. Of those who progressed, roughly two-thirds underwent mastectomy, and a small number became inoperable or developed distant spread. Overall, disease progression changed the surgical plan in about half a percent of all patients.23PubMed Central. Impact of Progression During Neoadjuvant Chemotherapy on Surgical Management of Breast Cancer That’s a low rate, but it’s not zero, and for the individual patient whose cancer grows past the point of operability, the consequences are serious.
The treatment itself can also complicate subsequent surgery. In esophageal cancer, patients who received neoadjuvant therapy before their operation had higher rates of lung complications, particularly pneumonia, and were more prone to anastomotic leakage, which is a breakdown at the surgical connection point.24PubMed Central. Assessment of safety during hospitalization for patients undergoing Surgery after neoadjuvant therapy for moderately advanced Esophageal cancer Radiation to the chest or pelvis before surgery can make tissues more fragile and harder to work with. And immunotherapy, while generally well tolerated, carries its own set of immune-related side effects that can delay surgery if they’re severe enough.
There are also practical burdens. Neoadjuvant treatment adds weeks to months to the overall treatment timeline. Patients undergo chemotherapy or immunotherapy, wait for recovery, have surgery, then potentially receive more treatment afterward. In a study modeling financial burden in breast cancer, neoadjuvant therapy emerged as one of the key clinical predictors of higher out-of-pocket costs for patients.25PubMed Central. Development of Machine Learning Algorithms for the Prediction of Financial Toxicity in Localized Breast Cancer Following Surgical Treatment
Neoadjuvant Therapy in Children
Pediatric cancers have their own relationship with neoadjuvant treatment, and in some ways, pediatric oncology was ahead of the curve. In children with solid tumors like Wilms tumor, neuroblastoma, and certain bone and soft-tissue cancers, the surgical approach has evolved over decades from aggressive upfront resection to a more tailored strategy that delivers chemotherapy first. The rationale is that an aggressive initial operation can cause unnecessary short- and long-term harm and may produce an incomplete resection, while also delaying the systemic chemotherapy that’s critical for treating cancer that has already spread microscopically. Neoadjuvant chemotherapy in pediatric solid tumors allows surgeons to plan a more precise, less morbid operation and helps control metastatic disease from the outset.
The I-SPY2 Model and Treatment Personalization in Breast Cancer
One of the most innovative uses of the neoadjuvant setting is as a testing platform for new drugs. The I-SPY2 trial, an ongoing adaptive clinical trial in breast cancer, randomizes patients with high-risk disease to various experimental regimens added to standard neoadjuvant chemotherapy. Because the tumor is still present during treatment, researchers can use pCR as a rapid readout to determine which drugs work in which molecular subtypes, dramatically accelerating the pace of drug development. Among over 1,000 patients enrolled in I-SPY2, about 47% achieved pCR overall, with rates of roughly 44% in triple-negative breast cancer and 51% in HER2-positive disease.26PubMed Central. Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial
The neoadjuvant approach creates a window that doesn’t exist in other settings. Before treatment, the tumor can be biopsied and its molecular features mapped. During treatment, imaging and blood tests can track whether it’s responding. After treatment, the surgical specimen reveals exactly what happened at the cellular level. That feedback loop is uniquely powerful. A patient who achieves pCR may be safely spared additional toxic therapy. A patient with significant residual disease can be switched to a different drug immediately, while there’s still time for it to matter. This kind of adaptive, response-guided care is increasingly the direction of modern oncology, and neoadjuvant therapy is the framework that makes it possible.